Autors:

CiteWeb id: 20090000100

CiteWeb score: 4575

DOI: 10.1056/NEJMoa072761

�Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.

The publication "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes" is placed in the Top 10000 of the best publications in CiteWeb. Also in the category Medicine it is included to the Top 1000. Additionally, the publicaiton "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes" is placed in the Top 1000 among other scientific works published in 2009.
Links to full text of the publication: